Patents by Inventor Philippe M. Rabbat

Philippe M. Rabbat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6531617
    Abstract: Enantiomerically enriched hydroxychromanones are obtained by the AlCl3-catalyzed intramolecular Friedel-Crafts acylation of the corresponding 3-phenoxy-2-alkylcarbonyloxy-propionic acid followed by cleavage of the carboxylate in the presence of an alkali metal peroxide or hydroperoxide. Enantiomerically enriched cis-aminochromanols can then be prepared by treating the hydroxychromanones with a hydroxylamine and hydrogenating the resulting oxime. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: March 11, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Karl Hansen, Paul Devine, Philippe M. Rabbat
  • Publication number: 20020095047
    Abstract: Enantiomerically enriched hydroxychromanones are obtained by the AlCl3-catalyzed intramolecular Friedel-Crafts acylation of the corresponding 3-phenoxy-2-alkylcarbonyloxy-propionic acid followed by cleavage of the carboxylate in the presence of an alkali metal peroxide or hydroperoxide. Enantiomerically enriched cis-aminochromanols can then be prepared by treating the hydroxychromanones with a hydroxylamine and hydrogenating the resulting oxime. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Application
    Filed: October 24, 2001
    Publication date: July 18, 2002
    Inventors: Karl Hansen, Paul Devine, Philippe M. Rabbat
  • Patent number: 6384244
    Abstract: cis-aminochromanols are obtained in high yield and with high selectivity over their trans counterparts by hydrogenating the corresponding oximes in the presence of a catalyst and an acid selected from HBr, HCl, and organic sulfonic acid. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: May 7, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian Davies, Karl Hansen, Paul N. Devine, Louis Matty, Jr., Yuan Cheng, Philippe M. Rabbat
  • Publication number: 20010056193
    Abstract: cis-aminochromanols are obtained in high yield and with high selectivity over their trans counterparts by hydrogenating the corresponding oximes in the presence of a catalyst and an acid selected from HBr, HCl, and organic sulfonic acid. The cis-aminochromanols can be employed as intermediates in the production of HIV protease inhibitors which are useful for treating HIV infection and AIDS.
    Type: Application
    Filed: May 11, 2001
    Publication date: December 27, 2001
    Inventors: Ian Davies, Karl Hansen, Paul N. Devine, Louis Matty,Jr., Yuan Cheng, Philippe M. Rabbat